Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coegin Pharma strengthens Danish pharmacy presence - VEXIENNE® expands to Køge and southern Zealand

COEGINPress release16.11.2026, 09.50

Coegin Pharma AB ("Coegin" or the "Company") today announces a collaboration with Køge Boholte Apotek, a pharmacy operator with four locations in Køge and southern Zealand, to introduce VEXIENNE® Hair Active X™ to its customers. The initial launch will cover two pharmacies before the end of 2026 and follows the collaboration with Taastrup Apotek announced on 13 November 2026.

With the two collaborations (Taastrup Apotek and Køge Boholte Apotek), VEXIENNE® will be introduced at five Danish pharmacies in Greater Copenhagen and on Zealand. Together with the recently announced agreement with MEDS in Sweden, they strengthen Coegin's Nordic distribution footprint and advance its strategy to scale Follicopeptide® through selected pharmacy, clinic and professional partners.

Hair Active X™ is a premium cosmetic gel serum powered by Follicopeptide®, Coegin's patented and clinically developed peptide technology for thinning hair. Deliveries to the pharmacies are planned for November, with in-store availability expected before year-end.

"Only days after announcing our collaboration with Taastrup Apotek, we are adding a second Danish pharmacy partner. The two complement each other very well: Taastrup Apotek with its strong presence in central and Greater Copenhagen, and Køge Boholte Apotek with its reach across Zealand and online. Both are led by forward-looking pharmacists, and together they give us a strong base in the Danish pharmacy channel," says Jens Eriksson, CEO of Coegin Pharma.

"Our customers ask for serious, science-based options for thinning hair, and we want to offer them a credible choice. Hair Active X™ fits well with the personal advice our staff give every day, and we look forward to offering it in our pharmacies," says Troels Ravn, pharmacy owner, Køge Boholte Apotek.

The initial introduction will take place at Køge Boholte Apotek in Køge and Rønnede Apotek on southern Zealand, with preparations under way for the planned launch before the end of 2026.

The agreement complements Coegin's existing private label partnerships and VEXIENNE® distribution model, supporting a broader and more diversified commercial footprint.

For further information, please contact:
Jens Eriksson, CEO, or Lars B. Rasmussen, CFO
Email: info@coeginpharma.com
Phone: 072-221 24 21

About Køge Boholte Apotek
Led by pharmacist Troels Ravn, Køge Boholte Apotek operates four pharmacies in Køge and southern Zealand: Køge Boholte Apotek, Ølby Apotek, Herfølge Apotek and Rønnede Apotek. The group also has a strong online presence, offering online ordering and home delivery of medicines. The pharmacies combine accessible healthcare products with qualified, personal advice on medicines and health-related products.

About Coegin Pharma
Coegin Pharma is a Swedish innovation company developing and commercializing advanced cosmetic technologies for hair and skin. Its flagship innovation, Follicopeptide®, is a patented, clinically developed peptide technology targeting hair thinning, commercialized through selected partners and the Company's VEXIENNE® brand. Coegin is also developing NPP-4, a next-generation cosmetic peptide innovation for skin tone enhancement.

With proprietary peptide technology, scalable in-house production and flexible commercial models, Coegin is building a differentiated platform for science-based cosmetic products.

Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The Company is headquartered in Lund, Sweden.

For more information, including company updates and social media links, visit www.coeginpharma.com

Attached files

261116-Pressrelease.pdf